Evidence map›Paper›PMID 34521999›Full record

ArticleEuropean journal of human genetics : EJHG2022

Establishing the phenotypic spectrum of ZTTK syndrome by analysis of 52 individuals with variants in SON.

Alexander J M Dingemans, Kim M G Truijen, Jung-Hyun Kim, Zahide Alaçam, Laurence Faivre, Kathleen M Collins, Erica H Gerkes, Mieke van Haelst, Ingrid M B H van de Laar, Kristin Lindstrom and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. [Zhu-Tokita-Takenouchi-Kim syndrome in a neonate].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Neurology. Genetics · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 8 countries.

Alexander J M Dingemans *Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Kim M G Truijen *Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Jung-Hyun KimMitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA.ORCID 0000-0001-7176-409X
Zahide AlaçamDenizli State Hospital, Denizli, Turkey.
Laurence FaivreCentre de Génétique, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, CHU de Dijon, 2 INSERM UMR1231, GAD, Université de Bourgogne Franche-Comté, Dijon, France.
Kathleen M CollinsDartmouth Hitchcock Medical Centre, Lebanon, NH, USA.
Erica H GerkesDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Mieke van HaelstDepartment of Clinical Genetics and Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Ingrid M B H van de LaarDepartment of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Kristin LindstromDivision of Genetics and Metabolism, Phoenix Children's Hospital, Phoenix, AZ, USA.
Mathilde NizonService de Génétique Médicale, CHU Nantes, Nantes, France.ORCID 0000-0003-2170-4210
James PaulingArrowe Park Hospital, Wirral, UK.
Edyta Heropolitańska-PliszkaDepartment of Immunology, Children's Memorial Health Institute, Warsaw, Poland.
Astrid S PlompDepartment of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Caroline RacineCentre de Génétique, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, CHU de Dijon, 2 INSERM UMR1231, GAD, Université de Bourgogne Franche-Comté, Dijon, France.ORCID 0000-0003-2378-5982
Rani SachdevCentre for Clinical Genetics, Sydney Children's Hospital Network, Sydney, Australia.
Margje SinnemaDepartment of Clinical Genetics, MUMC, Maastricht, The Netherlands.
Jon SkranesUnit for Child Neurology and Rehabilitation, Department of Pediatrics, Sørlandet Hospital, Arendal, Norway.
Hermine E Veenstra-KnolDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Eline A VerberneDepartment of Clinical Genetics and Amsterdam Reproduction & Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Anneke T Vulto-van SilfhoutDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Marlon E F WilstermanDepartment of Pediatrics, Nij Smellinghe, Drachten, The Netherlands.
Eun-Young Erin AhnDivision of Molecular and Cellular Pathology, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-8795-7734
Bert B A de VriesDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. bert.devries@radboudumc.nl.ORCID 0000-0002-0000-2917
Lisenka E L M VissersDepartment of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. lisenka.vissers@radboudumc.nl.ORCID 0000-0001-6470-5497
Radboud University Nijmegen · NLAmsterdam University Medical Centers · NLInserm · FRUniversity Medical Center Groningen · NLArrowe Park Hospital · GBChildren's Memorial Health Institute · PLDartmouth–Hitchcock Medical Center · USDenizli Devlet Hastanesi · TRErasmus MC · NLGénétique Médicale & Génomique Fonctionelle · FRMaastricht University Medical Centre · NLPhoenix Children's Hospital · USSørlandet Hospital Arendal · NOSydney Children’s Hospitals Network · AUUniversity of Alabama at Birmingham · USUSA Mitchell Cancer Institute · USZiekenhuis Nij Smellinghe · NL

Funding

SON-mediated RNA splicing in glioblastomaR01CA236911 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHN, ERIN EUN-YOUNG · 2020 to 2024
$1.8M
SON-mediated gene expression and leukemiaR01CA190688 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI AHN, ERIN EUN-YOUNG · 2016 to 2021
$1.7M
NCI NIH HHS R01 CA190688NCI NIH HHS R01 CA236911
6 · The paper itself

Abstract

Zhu-Tokita-Takenouchi-Kim (ZTTK) syndrome, an intellectual disability syndrome first described in 2016, is caused by heterozygous loss-of-function variants in SON. Its encoded protein promotes pre-mRNA splicing of many genes essential for development. Whereas individual phenotypic traits have previously been linked to erroneous splicing of SON target genes, the phenotypic spectrum and the pathogenicity of missense variants have not been further evaluated. We present the phenotypic abnormalities in 52 individuals, including 17 individuals who have not been reported before. In total, loss-of-function variants were detected in 49 individuals (de novo in 47, inheritance unknown in 2), and in 3, a missense variant was observed (2 de novo, 1 inheritance unknown). Phenotypic abnormalities, systematically collected and analyzed in Human Phenotype Ontology, were found in all organ systems. Significant inter-individual phenotypic variability was observed, even in individuals with the same recurrent variant (n = 13). SON haploinsufficiency was previously shown to lead to downregulation of downstream genes, contributing to specific phenotypic features. Similar functional analysis for one missense variant, however, suggests a different mechanism than for heterozygous loss-of-function. Although small in numbers and while pathogenicity of these variants is not certain, these data allow for speculation whether de novo missense variants cause ZTTK syndrome via another mechanism, or a separate overlapping syndrome. In conclusion, heterozygous loss-of-function variants in SON define a recognizable syndrome, ZTTK, associated with a broad, severe phenotypic spectrum, characterized by a large inter-individual variability. These observations provide essential information for affected individuals, parents, and healthcare professionals to ensure appropriate clinical management.

Indexed as

DNA-Binding ProteinsIntellectual DisabilityMinor Histocompatibility AntigensHumansMutation, MissensePhenotypeSyndromeDNA-Binding ProteinsMinor Histocompatibility AntigensSON protein, human

Identifiers

PMID34521999
PMCPMC8904542
OpenAlexW3200785218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.